Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and sale of various pharmaceutical products in China. The company offers traditional Chinese medicine formula granules; finished drugs, including xuebijing injections, low molecular weight heparin calcium injections, moxifloxacin hydrochloride sodium chloride injections, enoxaparin sodium injections, nadronexacin calcium injections, fasudil hydrochloride injections, ketorheic acid tromethamine injections, ibanoxetine sodium injections, Qingfei Sanjie pills, and Ping Wan anti-cancer pills; raw materials and excipients, such as pharmaceutical excipients, active pharmaceutical ingredients (APIs), and food additives; medical devices, including oxygen concentrators and portable oxygen concentrators; medical and health services; and intelligent supply chain services for pharmaceuticals and medical devices. It also provides chemical reagents, Western patent medicines, enteric casings, heparin sodium, food, beverages, seasonings, tea, candies, and traditional Chinese medicine decoction pieces; pharmaceutical equipment and self-owned housing leasing; pharmaceutical product and medical device research and development; technology consulting, transfer, and promotion; health management, business management, nutritional health, and health information consulting; wholesale and retail of electronic products; import and export of goods and technology; biopharmaceutical project management; project investment; technical service development, transfer, and consulting; consumer electronics and sporting goods sales; computer software and hardware development; general hospital services; nursing services for the elderly and disabled; medical management; diagnosis and treatment; and medical data research activities. The company exports its products to approximately 50 countries and regions. Tianjin Chase Sun Pharmaceutical Co.,Ltd was founded in 1996 and is headquartered in Tianjin, China.
